Market Closed -
Hong Kong S.E.
04:08:20 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
0.045
HKD
|
+7.14%
|
|
-2.17%
|
-54.55%
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
323.1
|
438.3
|
158.5
|
59.43
|
73.15
|
72.28
|
Enterprise Value (EV)
1 |
-612.1
|
-193.1
|
38.63
|
29.38
|
54.52
|
69.34
|
P/E ratio
|
-0.47
x
|
-1.42
x
|
-0.32
x
|
-0.09
x
|
-0.31
x
|
-0.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.12
x
|
0.18
x
|
0.1
x
|
0.05
x
|
0.06
x
|
0.06
x
|
EV / Revenue
|
-0.23
x
|
-0.08
x
|
0.03
x
|
0.02
x
|
0.04
x
|
0.05
x
|
EV / EBITDA
|
2.39
x
|
0.7
x
|
-0.08
x
|
-0.08
x
|
-0.36
x
|
-0.98
x
|
EV / FCF
|
-
|
1,010,852
x
|
-132,667
x
|
446,314
x
|
1,963,105
x
|
101,573,068
x
|
FCF Yield
|
-
|
0%
|
-0%
|
0%
|
0%
|
0%
|
Price to Book
|
0.17
x
|
0.25
x
|
0.13
x
|
0.1
x
|
0.18
x
|
0.23
x
|
Nbr of stocks (in thousands)
|
304,054
|
358,783
|
386,313
|
386,313
|
556,291
|
667,550
|
Reference price
2 |
1.063
|
1.222
|
0.4102
|
0.1538
|
0.1315
|
0.1083
|
Announcement Date
|
11/19/18
|
10/24/19
|
10/15/20
|
10/21/21
|
10/20/22
|
10/19/23
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,646
|
2,424
|
1,510
|
1,185
|
1,274
|
1,297
|
EBITDA
1 |
-255.9
|
-276.5
|
-472.2
|
-346.3
|
-151.2
|
-70.62
|
EBIT
1 |
-300.6
|
-299.8
|
-502.6
|
-443.5
|
-169.7
|
-86.39
|
Operating Margin
|
-11.36%
|
-12.37%
|
-33.28%
|
-37.42%
|
-13.33%
|
-6.66%
|
Earnings before Tax (EBT)
1 |
-642.6
|
-263.9
|
-492.2
|
-670.8
|
-188
|
-112.1
|
Net income
1 |
-611.3
|
-265.6
|
-491.4
|
-675.4
|
-187.6
|
-105.4
|
Net margin
|
-23.1%
|
-10.96%
|
-32.54%
|
-56.99%
|
-14.73%
|
-8.13%
|
EPS
2 |
-2.244
|
-0.8576
|
-1.275
|
-1.748
|
-0.4266
|
-0.1807
|
Free Cash Flow
|
-
|
-191.1
|
-291.1
|
65.82
|
27.77
|
0.6826
|
FCF margin
|
-
|
-7.88%
|
-19.28%
|
5.55%
|
2.18%
|
0.05%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/19/18
|
10/24/19
|
10/15/20
|
10/21/21
|
10/20/22
|
10/19/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
935
|
631
|
120
|
30.1
|
18.6
|
2.94
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-191
|
-291
|
65.8
|
27.8
|
0.68
|
ROE (net income / shareholders' equity)
|
-
|
-14.6%
|
-33.1%
|
-74.2%
|
-38.2%
|
-29.3%
|
ROA (Net income/ Total Assets)
|
-
|
-8.85%
|
-18%
|
-22.6%
|
-11.8%
|
-6.84%
|
Assets
1 |
-
|
3,000
|
2,736
|
2,989
|
1,589
|
1,540
|
Book Value Per Share
2 |
6.300
|
4.820
|
3.220
|
1.490
|
0.7300
|
0.4700
|
Cash Flow per Share
2 |
3.060
|
1.750
|
0.3400
|
0.0900
|
0.1000
|
0.0600
|
Capex
1 |
77.8
|
3.36
|
95.7
|
1.9
|
0.1
|
0.06
|
Capex / Sales
|
2.94%
|
0.14%
|
6.34%
|
0.16%
|
0.01%
|
0%
|
Announcement Date
|
11/19/18
|
10/24/19
|
10/15/20
|
10/21/21
|
10/20/22
|
10/19/23
|
|
1st Jan change
|
Capi.
|
---|
| -54.55% | 3.84M | | +17.35% | 71.39B | | +5.38% | 8.59B | | +6.69% | 8.19B | | -20.96% | 7.91B | | +0.49% | 4.54B | | +17.12% | 4.31B | | -3.38% | 3.93B | | -2.61% | 3.86B | | +22.08% | 3.64B |
Pharmaceuticals Wholesale
|